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Abstract: The SARS-CoV-2 virus utilizes angiotensin converting enzyme (ACE-2) for cell entry and
infection. This enzyme has important functions in the renin-angiotensin aldosterone system to
preserve cardiovascular function. In addition to the heart, it is expressed in many tissues including
the lung, intestines, brain, and kidney, however, its functions in these organs are mostly unknown.
ACE-2 has membrane-bound and soluble forms. Its expression levels are altered in disease states
and by a variety of medications. Currently, it is not clear how altered ACE-2 levels influence
ACE-2 virulence and relevant complications. In addition, membrane-bound and soluble forms are
thought to have different effects. Most work on this topic in the literature is on the SARS-CoV virus
that has a high genetic resemblance to SARS-Co-V-2 and also uses ACE-2 enzyme to enter the cell, but
with much lower affinity. More recent studies on SARS-CoV-2 are mainly clinical studies aiming at
relating the effect of medications that are thought to influence ACE-2 levels, with COVID-19 outcomes
for patients under these medications. This review paper aims to summarize what is known about
the relationship between ACE-2 levels and SARS-CoV/SARS-CoV-2 virulence under altered ACE-2
expression states.
Keywords: ACE-2; SARS-CoV; COVID-19; shedding; ACE inhibitors; RAAS; angiotensin receptor
blockers; ARDS
1. Introduction
The way a virus can infect an organism is via binding to its specific surface receptors on
the cell. Hence, the expression and tissue-specific distribution of such receptors determine
the pathogenesis of the disease. Similar to the original severe acute respiratory syndrome
coronavirus (SARS-CoV), SARS-CoV-2 utilizes the peptidase angiotensin-converting en-
zyme 2 (ACE-2) for cell entry [1]. Therefore, ACE-2 expression in different tissues and
ACE-2’s interaction with SARS-CoV-2 are critical for the progression from early infection
to severe coronavirus disease 2019 (COVID-19). For the majority of cases, COVID-19
patients present typical symptoms of inflammation in the lung, and acute respiratory
distress syndrome (ARDS) in severe cases, showing that the lung is the primary target
of the virus. Lung alveolar type 2 (AT2) cells highly express ACE-2, which explains the
susceptibility of the organ to SARS-CoV-2 infection. However, the function of this promi-
nent ACE-2 expression in the lung other than enabling virus entry is not clear. As an
important member of the renin-angiotensin aldosterone system (RAAS) pathway, ACE-2
is a transmembrane protein best known for its homeostatic role in counterbalancing the
effects of ACE and Angiotensin II (ANG-II) on the cardiovascular system. ACE-2 can be
found as membrane-bound or soluble forms, both of which can actively cleave ANG-II.
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Considering ACE-2’s primary function is ANG-II cleavage, the reason for higher expres-
sion in pulmonary epithelial cells compared to in pulmonary endothelial cells in unclear.
Furthermore, ACE-2 is also highly expressed in cardiomyocytes, kidneys, intestines, male
reproduction organs, and the brain [2]. It is unclear whether the non-pulmonary expression
of ACE-2 and the relevant viral infection is responsible for other clinical complications
of SARS-CoV-2, and this requires further investigation. Some of the symptoms, such as
loss of smell and gastrointestinal complications, suggest SARS-CoV-2 infection in ACE-2
expressing tissues in COVID-19. Tissue-specific ACE-2 expressions, as well as circulating
soluble concentrations, were shown to be altered in diseased states such as viral infection
and cardiac disease [3,4]. Furthermore, certain anti-hypertensive medications are known
to alter ACE-2 levels [5]. Therefore, there is a great interest in revealing a mechanistic
relationship (if it exists) between ACE-2 levels and SARS-CoV-2 virulence/related com-
plications, and how this relationship is affected in diseased states. This review aims to
summarize what is known about this relationship and the critical points to be investigated
in the future.
2. SARS-CoV-2 and ACE-2
Coronavirus entry into cells via membrane-bound ACE-2: COVID-19 has become a
deadly pandemic affecting all countries. A novel coronavirus, previously named 2019-
nCoV, and now known as SARS-CoV-2, was discovered to be the cause of the disease [6].
A coronavirus has spike proteins, commonly called S-protein, distributed on its lipid layer.
The virus binds to the specific surface receptors on the target cell’s membrane for cellular
entry, leading to replication and infection [3]. Coronavirus S-protein has two functional
units, S1 and S2. While S1 contains the receptor-binding domain (RBD) for binding to
ACE-2, which is the SARS-CoV-2’s host receptor, the function of S2 is fusion into the host
cell membrane. Following the binding of the virus to ACE-2 by S1, the cleavage site of S2 is
exposed and cleaved by the host protease, which was shown to be a critical step for virus
infection [3]. While the S-protein homology between SARS-CoV-2 and SARS-CoV was
relatively low, with a similarity of amino acid sequence 76.47%, S-protein RBD domains
were highly similar, resulting in close van der Waals bond and electrostatic properties in
the interaction interface, which shows the acting receptor of SARS-CoV-2 was the same
as that of SARS-CoV. Both the original SARS-CoV and recent SARS-CoV-2 utilize ACE-2
as their host receptor. However, the affinity of SARS-CoV-2 S-protein against ACE-2 is
about 10–20 times higher than that of SARS-CoV S-protein, which is likely to explain highly
infectious characteristics of SARS-CoV-2. This high affinity raised the attention to ACE-2
enzyme, its tissue specific expressions and up-/downregulation in its different forms.
The human ACE-2 gene contains 18 exons located on the short arm of the X chromosome.
Its molecular weight is 120 kD encoding 805 amino acids [7]. As a transmembrane protein,
ACE-2 consists of a signal peptide at the amino-terminal, a single metalloproteinase active site,
a transmembrane domain, and a small cytoplasmic domain at the carboxyl terminus. Similar to
ACE, ACE-2 is a cleavable enzyme that releases its extracellular portion into the circulation as
soluble ACE-2, a mechanism known as shedding. Transmembrane and cytoplasmic domains
are missing in the soluble ACE-2 but it still has an enzymatic activity [6].
ACE-2 mediated coronavirus entry into the host cell can happen in two independent
ways (Figure 1). In the first way, the virus enters the cell via endocytosis. Here, when
the virus docks onto ACE-2, the catalytic extracellular domain of ACE-2 is cleaved off,
controlled by a specific protease, ADAM17, resulting in internalization of the transmem-
brane domain. This is followed by the fusing of the viral particles with the assistance of
Clathrin and the transport of the virus from the cell membrane to the cytoplasm, aided by
the intracellular structure of ACE-2 [8]. The second way of cell entry is membrane fusion,
again mediated by ACE-2 and also by transmembrane serine protease 2 (TMPRSS2). Here,
following the binding of the SARS S-protein to ACE-2, processing by TMPRSS2 allows
direct fusion at the cell surface [9]. The critical role of TMPRSS2s for SARS-CoV-2 infection
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was recently confirmed [10]. While TMPRSS2 and ADAM17 compete for processing ACE-2,
only cleavage by TMPRSS2 enhances SARS-S protein-driven entry [6].
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coronavirus in two distinct ways. The first one is Clathrin and ADAM 17-dependent endocytosis, and the second one is 
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2.1. Functions and Distribution of ACE-2 in the Body 
Tissue-Specific ACE-2 expression: SARS-CoV-2 is accepted as an airborne transmit-
ted respiratory virus. Therefore, the virus must initially infect the respiratory tract cells. 
In situ RNA analysis and single-cell sequencing of the human respiratory tract revealed 
that ACE-2 is highly expressed in nasal epithelial cells and lesser expression in bronchial 
epithelial cells and AT2 cells [11]. In vitro studies were consistent with that finding: upper 
respiratory tract cells were more permissive to SARS-CoV-2 infection than lower respira-
tory tract cells [1]. Recently, Zhao and colleagues revealed that, while ACE-2 is expressed 
only in 0.64% of pulmonary cells, the majority of the expression is concentrated on AT2 
cells (about 83%). Therefore, SARS-CoV-2 seems to efficiently utilize AT2 cells for repro-
duction and spread. The high AT2 expression of ACE-2 may be the reason for severe al-
veolar injury following the initial infection. Previous studies demonstrated that, as well 
as the lung, ACE-2 is widely distributed in multiple other tissues including the heart, vas-
cular smooth muscle cells, kidney, gastrointestinal tract, testis, adipose tissue, and brain 
tissue [3]. ACE-2 is expressed mainly in the vascular endothelial cells of these organs [12]. 
Xu and colleagues performed RNA-Seq for 14 organs and showed that ACE-2 is highly 
expressed in (from highest to lowest) the colon, gallbladder, heart muscle, kidney, epidi-
dymis, breast, ovary, lung, prostate, esophagus, tongue, liver, pancreas, and cerebellum 
[13] (Figure 2). The same study revealed high ACE-2 expression in oral cavity epithelial 
Figure 1. SARS-CoV’s viral invasion of the host cell via a membrane-bound ACE-2 receptor.
ACE-2 mediates entry of coronavirus in two distinct ways. The first one is Clathrin and ADAM
17-dependent endocytosis, and the second one is TMPRSS2-dependent membrane fusion. Figure
replicated from [6] with permission.
2.1. Functions and Distribution of ACE-2 in the Body
Tissue-Specific ACE-2 expres ion: SARS-CoV-2 is a cepted as an airborne transmitted
respiratory virus. Therefore, the virus must i iti lly infect the re piratory tract c lls. In situ
RNA analysis and single-cell sequencing of the human respiratory tract r vealed t at ACE-2
is highly expressed in nasal epithelial cells and lesser expression in bronchial epit elial cells
and AT2 cells [11]. In vitro studies were consistent with that finding: upper respiratory tract
cells were more permissive to SARS-CoV-2 infection than lower respiratory tract cells [1].
Recently, Zhao and colleagues revealed that, while ACE-2 is expressed only in 0.64% of
pulmonary cells, the majority of the expression is concentrated on AT2 cells (about 83%).
Therefore, SARS-CoV-2 seems to efficiently utilize AT2 cells for reproduction and spread.
The high AT2 expression of ACE-2 may be the reason for severe alveolar injury following the
initial infection. Previous studies demonstrated that, as well as the lung, ACE-2 is widely
distributed in multiple other tissues including the heart, vascular sm oth muscle cells,
kidney, gastrointestinal tract, testis, adipose tissue, and brain tissue [3]. ACE-2 i express d
mainly in the vascular endothelial cells of these organs [12]. Xu and colleagues performed
RNA-Seq for 14 organs and showed that ACE-2 is highly expressed in (from highest
to lowest) the colon, gallbladder, heart muscle, kidney, epididymis, breast, ovary, lung,
prostate, esophagus, tongue, liver, pancreas, and cerebellum [13] (Figure 2). The same study
revealed high ACE-2 expression in oral cavity epithelial cells, consistent with initiation
of infection at the upper respiratory tract. Hikmet and colleagues analyzed the protein
expression profiles in a variety of human tissues. ACE-2 was mainly expressed in renal
tubules, intestinal enterocytes, cardiomyocytes, vasculature gallbladder, male reproductive
cells, ductal cells, placental trophoblasts, and eye [14]. Interestingly, lung ACE-2 expression
was low with expression constricted to mainly AT2, cells consistent with other studies.
Cellular distribution of ACE-2 in these tissues was constricted to mainly in endothelial cells,
epithelial cells, and immune cells such as macrophages [15]. Expression profiles partly
reflect the SARS-CoV-2 infection profile, such as common gastrointestinal tract infections
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with detectable viral RNA in the stool for about 30% of COVID-19 patients [1]. Acute
kidney injury and heart injury are common in COVID-19, consistent with high ACE-2
expression in these organs [6,16].
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process known as ectodomain shedding. Shedding is a key post-translational modifica-
tions mechanism for transmembrane proteins such as ACE-2. Therefore, ACE-2 can be 
found as membrane-bound or as soluble/circulating within the body [19]. Because the cat-
alytic site of ACE-2 is located in the ectodomain site, the release of the catalytically active 
part of the enzyme following shedding can influence the enzymatic activities in the cellu-
lar microenvironment, but also can influence distal tissue once the soluble enzyme mi-
grates to distal organs via systemic circulation. Additionally, since it is a surface receptor, 
intracellular signaling and gene expression can be initiated once a ligand binds to it [20] 
or as a response to a viral infection such as SARS-CoV [21]. Therefore, the ectodomain of 
ACE-2 plays an important role in its function, and ectodomain shedding could influence 
both ACE-2-expressing cells/tissues and other neighboring cells/tissues. Shedding of the 
ectodomain part of ACE-2 and the release of the soluble form were shown to exist in var-
ious diseases including heart disease, kidney disease, lung infection, and ARDS [19]. 
2.4. ACE-2 Shedding and Viral Infection 
To improve therapies, it is important to understand how ACE-2 shedding, as well as 
membrane-bound and soluble ACE-2 levels, affect SARS-CoV-2 infection. Li and col-
leagues were the first groups showing that the S1 domain of the SARS-CoV S-protein 
binds efficiently to ACE-2 isolated from SARS-CoV-permissive Vero E6 cells [21]. When a 
major portion of the cytoplasmic domain of ACE-2 was deleted, there was no effect on S-
driven infection, suggesting that the cytoplasmic domain is not critical for receptor func-
tion for infection. Another important finding was that a soluble form of ACE-2 could suc-
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2.3. ACE-2 in Disease
Membrane-Bound and Soluble forms of ACE-2, and Mechanism of Shedding
As a transmembrane glycoprotein enzyme, ACE-2 is composed of a short cytoplasmic
domain, a transmembrane domain, a catalytic ectodomain, and an amino-terminal signal
peptide. Similar to most other transmembrane proteins, ACE-2 undergoes proteolytic
cleavage from the cell surface to release its catalytic ectodomain part as a soluble form, a
process known as ectodomain shedding. Shedding is a key post-translational modifications
mechanism for transmembrane proteins such as ACE-2. Therefore, ACE-2 can be found
as membrane-bound or as soluble/circulating within the body [19]. Because the catalytic
site of ACE-2 is located in the ectodomain site, the release of the catalytically active part
of the enzyme following shedding can influence the enzymatic activities in the cellular
microenvironment, but also can influence distal tissue once the soluble enzyme migrates
to distal organs via systemic circulation. Additionally, since it is a surface receptor, intra-
cellular signaling and gene expression can be initiated once a ligand binds to it [20] or
as a response to a viral infection such as SARS-CoV [21]. Therefore, the ectodomain of
ACE-2 plays an important role in its function, and ectodomain shedding could influence
both ACE-2-expressing cells/tissues and other neighboring cells/tissues. Shedding of
the ectodomain part of ACE-2 and the release of the soluble form were shown to exist in
various diseases including heart disease, kidney disease, lung infection, and ARDS [19].
2.4. ACE-2 Shedding and Viral Infection
To improve therapies, it is important to understand how ACE-2 shedding, as well
as membrane-bound and soluble ACE-2 levels, affect SARS-CoV-2 infection. Li and col-
leagues were the first groups showing that the S1 domain of the SARS-CoV S-protein binds
efficiently to ACE-2 isolated from SARS-CoV-permissive Vero E6 cells [21]. When a major
portion of the cytoplasmic domain of ACE-2 was deleted, there was no effect on S-driven
infection, suggesting that the cytoplasmic domain is not critical for receptor function for
infection. Another important finding was that a soluble form of ACE-2 could successfully
block the association of the S1 domain with the cells. Viral replication was inhibited when
the cells were cultured in the presence of an anti-ACE-2 antibody. Hofmann and colleagues
showed that ACE-2 expression levels in various cell lines directly correlated with the sus-
ceptibility to SARS-CoV S-driven infection. They also demonstrated that pre-incubation
of cell cultures with soluble ACE-2 ectodomain inhibits SARS-CoV S-driven infection in a
dose-dependent manner, further confirming that soluble ACE-2 can effectively block the
binding of SARS-CoV S-protein to membrane-bound ACE-2 [22]. These findings directed
interest to mechanisms for ACE-2 shedding, which would increase soluble ACE-2 levels
and inhibit viral infection. Lambert and colleagues investigated the involvement of several
ADAM family proteins, which largely mediate the shedding of membrane proteins [23].
Ablation of ADAM17 cells in HEK293 and Huh7 cells resulted in reduced ACE-2 shedding,
whereas ADAM17 overexpression significantly increased shedding, providing direct evi-
dence for ADAM17’s direct involvement in regulating the ectodomain shedding of ACE-2.
Haga and colleagues showed that shedding of the ectodomain of ACE-2 depends on the
TNF-alpha-converting enzyme (TACE) and in contrast to a study by Li and colleagues,
they found that cytoplasmic tail is required for shedding and the process was accompanied
by TNF-alpha production and tissue damage [24]. In relevance to SARS-CoV, knockdown
of TACE or deletion of the cytoplasmic domain of ACE-2 blocked infection of the virus.
These findings provide evidence for modulation of TACE activity by SARS-CoV through
ACE-2’s cytoplasmic domain. In addition to facilitating the viral entry, the same domain
causes tissue damage via the production of TNF-alpha.
Using recombinant SARS-S protein, Glowacka and colleagues showed that SARS-S
efficiently engages to ACE-2 on Vero-6 cells, correlating with efficient induction of ACE-2
shedding. Binding of the viral S-protein resulted in the shedding of soluble ACE-2 into
the cellular supernatants, and also reduced membrane-bound ACE-2 expression, which
suggests that the shedding of ACE-2 contributes to the downregulation of ACE-2 expression
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in the context of SARS-CoV infection [25]. A following study showed that ACE-2 can also
be processed by TMPRSS2, and it was suggested that ACE-2 cleavage via TMPRSS2 might
increase SARS-S-mediated cellular entry [26]. Type II transmembrane serine proteases
(TTSPs) are mainly found on the surface of airway epithelial cells [27]. These were shown to
facilitate the entry of multiple respiratory viruses, including human influenza viruses [28]
and SARS-CoV [29]. The authors evaluated several TTSPs in their ability to activate
S protein entry into 293 T cells and identified that TMPRSS2 enhanced S-mediated entry,
more than other tested TTSPs. Since TMPRSS2 is highly expressed in epithelial cells lining
the nose, trachea, and distal airways, including type I and type II alveolar cells, TMPRSS2
might play role in lower-airway SARS-CoV and SARS-CoV-2 infections.
In a more recent study, Heurich and colleagues studied and compared TMPRSS2 and
ADAM17 in ACE-2 cleavage [9]. They found that SARS-CoV infection is facilitated by
TMPRSS2 via two independent mechanisms: while ACE-2 cleavage promotes viral uptake,
cleavage of SARS-S activates the protein for membrane fusion. They also demonstrate that
ADAM17 competes with TMPRSS2 for ACE-2 processing, but SARS-S-driven entry was not
modulated by ADAM17 activity. In addition, the study demonstrated that TMPRSS2 does
not facilitate ACE-2 shedding and even interferes with ADAM17-regulated ACE-2 shedding,
suggesting that ADAM17 and TMPRSS2 cleave ACE-2 at different sites. Therefore, while
ADAM17 enhances the shedding of ACE-2 and increasing soluble ACE-2, TMPPRSS2
interferes with this and prevents the shedding of ACE-2 (Figure 4). These findings suggest
that ADAM17 is the major shedding enzyme for ACE-2, and ADAM17-shedded ACE-2
(circulating ACE-2) protects lungs from the viral infection. While there is evidence for
TMPRSS2 expression inhibiting the ADAM17-regulated shedding of ACE-2, it is not clear
how TMPRSS2 competes with ADAM17 in cleaving ACE-2 during SARS-CoV or SARS-
CoV-2 infections. Even though SARS-CoV/SARS-CoV-2 can enter a target cell via two
ways, which are a fusion of viral membrane and endocytosis (Figure 2), viral membrane
fusion is 100 times more efficient in terms of viral replication. Therefore, even though
ADAM17-regulated ectodomain shedding of ACE-2 could induce viral entry through
endocytosis, this would not be as effective as SARS-CoV/SARS-CoV-2 cell entry through
fusion regulated by TMPRSS2, for which ADAM17 is not needed [12].
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body [30]. ACE-2 is a crucial component of the renin–angiotensin–aldosterone system 
(RAAS) [17]. The RAAS system is significant in the homeostasis of respiratory and cardio-
vascular systems [31]. ACE-2 converts ANG-II into the protective lung ANG-(1–7) and 
ANG-(1–9) through a pathway, catalyzing and preventing Angiotensin type I receptor 
(AT1R) activation, and, thus, ACE-2 function in the opposing manner to counterbalance 
ACE [32]. It has been previously shown by Papp et al. [33] that AT1R is a probable cause 
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cells in rats and humans. In addition, AT1R is highly expressed and it mediates signaling 
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2.5. ACE-2 and ARDS
The lung itself can be very prone to viral infections, more than any other organ,
since type II alveolar epithelial cells produce 83% of the cells that express ACE-2 in the
human body [30]. ACE-2 is a crucial component of the renin–angiotensin–aldosterone
system (RAAS) [17]. The RAAS system is significant in the homeostasis of respiratory and
cardiovascular systems [31]. ACE-2 converts ANG-II into the protective lung ANG-(1–7)
and ANG-(1–9) through a pathway, catalyzing and preventing Angiotensin type I receptor
(AT1R) activation, and, thus, ACE-2 function in the opposing manner to counterbalance
ACE [32]. It has been previously shown by Papp et al. [33] that AT1R is a probable cause
for apoptosis in lung alveolar epithelial cells in response to ANG-II in alveolar epithelial
cells in rats and humans. In addition, AT1R is highly expressed and it mediates signaling
effects in pulmonary and cardiac tissues, causing inflammation, pro-fibrotic signaling, and
tissue remodeling [34]. In addition, ANG-II has the capacity to release pro-inflammatory
cytokines, resulting in eventually what is known as cytokine storm. It was also shown by
Ismael-Badarneh that ANG-II decreases the rate of the clearance of alveolar fluids. Overall,
it can be negative for pulmonary tissues, in particular, and a great factor in the injuries,
hence the role of ACE-2 arises as a protective enzyme for lungs [35].
In their pioneering work, Imai and colleagues showed that inducing ARDS in wild-
type mice resulted in a dramatic reduction in lung ACE-2 expression, suggesting ACE-2
downregulation might be causing the severe acute lung pathologies in SARS-CoV [36].
Knocking out ACE-2 almost completely attenuated acute lung injury. Importantly, injection
of recombinant human ACE-2 into acid-treated ACE-2 knockout mice as well as to the
wild-type mice decreased the degree of acute lung injury significantly. In their follow-
up work, the same group investigated lung ACE-2 expressions and ARDS in SARS-CoV
infected mice [37]. Both ACE-2 knockout and control wild-type mice were infected with
SARS-CoV. Similar to previous reports, when wild-type mice were infected, large amounts
of the infectious virus could be recovered from the lungs. However, when the ACE-2
knockout mice were infected, only a very low quantity of virus could be extracted from
the lung. Interestingly, a viral infection of the wild-type mice caused mild pathological
changes in the lungs and decreased pulmonary ACE-2 expression. For the knock-out mice,
pathological alterations following viral infection were reduced compared to wild-type mice.
To confirm whether SARS-CoV S-protein could affect the severity of acute lung injury,
they treated both wild-type and knock-out animals with SARS-CoV S-protein. Similarly,
spike protein administration worsened acid-induced acute lung injury in wild-type mice,
but did not influence the severity of lung injury in knock-out animals, showing that the
effect of S-protein on acute lung injury depends on ACE-2. These findings suggest, not the
viral replication within the cell but the inactivation of ACE-2 following the docking of the
spike protein is the main factor for lung injury in SARS-CoV/SARS-CoV-2 infections. To
further demonstrate the beneficial effect of ACE-2 expression in ARDS, Li and colleagues
generated a pulmonary ACE-2 over-expression model by Lentiviral ACE-2 cDNA or ACE-2
shRNA administration into the lungs of SD rats [38]. The animals were exposed to LPS
to induce ARDS. ACE-2 overexpression significantly prevented LPS-induced lung injury
and inflammatory response. In contrast to this finding, Pinto and colleagues examined
more than 700 lung samples from severe COVID-19 patients who suffered from several
comorbidities, and revealed high pulmonary ACE-2 expression in these patients, compared
to healthy individuals [39].
The mechanism of shedding cannot be thought of as an entirely understood mecha-
nism, as it has been gaining a wider attention in order to become understood, especially
with the emergence of COVID-19 and the increasing interest in the role of ACE-2. It has been
suggested that the shedding of ACE-2 might trigger pro-inflammatory response [40,41].
ACE-2 shedding seems to be more inducible through two means: (1) viral infection re-
sponse, and (2) immunological reaction [42]. The former was clearly understood with the
emergence of SARS-COV in 2002–2003 [23]. As for the latter, it was suggested after the
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research of Jia et al., which manifested difference in primary airway epithelial cells and
Calu-3-cell line due the ACE-2 shedding [15].
As might be understood, ADAM17 plays a crucial role in ACE-2 shedding into sACE-2.
The cleavage of membrane anchor occurs through ADAM17, and it underlies its occurrence
in body fluid as the AT receptor upregulates ADAM17, resulting in an increase in sACE-2,
resulting in a decrease in SARS-COV-2 entry as the virus will interact with the soluble
form instead of interacting with mACE-2 and invade the cells [43]. In addition, it is worth
highlighting that the cleavage of mACE-2 occurs in a region called juxtamembrane, and
its retention on the cell membrane is regulated by the binding of calmodulin, and as the
calmodulin is inhibited, the scACE-2 is increasingly released [44]. In addition, Imai et al.
found that ACE-2 has the capacity to cleave the C-terminal residue from Apelin [45]. This is
crucial as Apelin’s receptor and agonist APJ and agonist apelin-13 protect the lung through
the mechanism of reducing ANG-II.
In 2012, El-Hashim et al. showed that ACE-2 may reduce the inflammations in the
lung via what is known as ANG 1–7/MasR axis. In their research model of murine asthma,
they found that it reduced eosinophil (Figure 5) [46]. They used a mouse model for allergic
asthma and they assisted lungs to quantify goblet cell, perivascular, and peribronchal
inflammation and fibrosis. In addition, they made a biochemical analysis of ERK1/2 and
IκB-α. Furthermore, the effect of Ang-(1–7) on the proliferation of human peripheral blood
mononuclear cells (HPBMC) was investigated. In their results, they found that Ang-(1–7)
attenuated ovalbumin-induced increase in the otal cell counts, eosinophils, lymphocytes
and neutrophil. On the other hand, decreased the ovalbumin-induced perivascular and
peribronchial inflammation, fibrosis and goblet cell hyper/metaplasia, as well as decreasing
the ovalbumin-induced increase in the phosphorylation of ERK1/2 and IκB-α. The authors
concluded that ANG 1–7 via MAS1 receptor acts as an ant-inflammatory pathway in
allergic asthma [47]. Reddy et al. demonstrated that in ARDS patients, it was found that
the ratio of ANG 1–7 was higher compared to ANG-I among survivors [48].
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Recently, clinical investigators examined seven lungs obtained during autopsy from
patients who died from COVID-19 and compared them with seven lungs obtained during
autopsy from patients who died from ARDS secondary to influenza A (H1N1) infection
and 10 age-matched, uninfected control lungs. In their findings, they found a significant
increase in the numbers of ACE2-positive cells in the lungs from patients with Covid-19
and from patients with influenza than in those from uninfected controls. In their results,
they found that a great positive number of endothelial ACE2-positive, as well as changes
in endothelial morphology [49].
The analysis of ACE2 expression in lungs reveals that it is very low and limited to
a small fraction of type II alveolar epithelial cells (around 1%) [50] and, surprisingly, in
both mRNA and protein levels [51], other types of cells release traces amounts [30,52].
As stated earlier, there are four types of isoforms of ACE2: (1) membrane bound or full
length mACE2; (2) Soluble ACE2 sACE2; (3) Isoform 3 of ACE2, known as cACE2 or
isoform 3; and (4) newly identified dACE2 [53]. Interestingly enough, it has been recently
discovered that it is majorly located and expressed in differentiated airway epithelial cells,
especially in cells of the upper airways. Previously, it was suggested that ACE2 is an
interferon-simulated gene [54,55], but here the authors report that the discovery of the
novel transcriptionally independent isoform-designated dACE2 is the interferon-simulated
one, and no other isoforms. Perhaps this was not discovered earlier because 3’-scRNA-seq
methods do not discriminate between ACE2 and dACE2. In their findings, the authors also
found that normal primary bronchial respiratory cells are the baseline expression levels of
dACE2, and they are further strongly induced by IFN treatments. This comes in agreement
with Zhuang et al.’s speculations that AE2 can be upregulated by viruses or through the
simulation of inflammatory cytokines, such as interferons [56].
In 2010, Wosten-van Asperen et al. investigated the role of ACE and ACE2 in animal
models in LPS-induced ARDS. The animals were treated with losartan (ANG-II receptor
antagonist), or with a protease-resistant, cyclic form of Ang-(1–7) [cAng-(1–7)]. In their
results, they found that in treated rats that are LPS-exposed as well, BALF ACE2 activity
and Ang-(1–7) levels were significantly higher in both treatment groups compared with
the placebo group [57]. In 2020, Kimura et al. demonstrated whether IL-13 (a potent
mediator of type 2 inflammation) modulates ACE2 and TMPRSS2 in airway epithelial
cells. They determined the effects of IL-13 on ACE2 and TMPRSS2 expression in vivo
in primary airway epithelial cells, from participants that have type 2 asthma. In their
results, they found a significant role of IL-13 was to reduce ACE2 and increase TMPRSS2
expression in epithelial and nasal airways. In addition, they found out that ACE2 was
negatively associated with type 2 cytokines. On the other hand, TMPRSS2 was positively
associated with type 2 cytokines. ACE-2 and TMPRSS2 are therefore modulated by type 2
inflammation in the upper and lower airways. This was found to be important for asthma
and atopy setting in COVID-19 infection, since SARS-CoV-2 cell entry depends on ACE-2
and TMPRSS2 [58].
Liu and colleagues showed that the Angiotensin-II level in the plasma sample from
SARS-CoV-2-infected patients was significantly elevated and linearly associated with viral
load and lung injury, suggesting decreased ACE-2 expression and function in these patients,
consistent with previous animal work on SARS-CoV [59]. Similar to studies for SARS-CoV,
a previous study on influenza A (H7N9) demonstrated that circulating ACE-2 protects
the lung against virus-induced acute lung injury [60]. Knocking out ACE-2 in mice led
to severe lung damage when the animal was infected with H5N1, and treatment of these
animals with human ACE-2 attenuated the lung damage. These findings provide strong
evidence for the protective roles of soluble as well as pulmonary ACE-2 against non-viral
ARDS and viral ARDS from SARS-CoV-2 [61].
Sodhi et al. investigated the effects on des-Arg9 bradykinin (DABK) in airway epithe-
lial cells based on a hypothesis that DABK is a biological substrate of ACE2 in the lung,
and ACE2 has a significant role in the pathogenesis of acute lung inflammation through
modulating DABK/bradykinin receptor B1 (BKB1R) axis signaling. In their results, they
Int. J. Mol. Sci. 2021, 22, 6703 10 of 18
found that ACE2 function in the lungs of the mice in the setting of endotoxin inhalation
led to the activation of the DABK/BKB1R axis releasing pro-inflammatory chemokines,
such as C-X-C motif chemokine 5 (CXCL5), macrophage inflammatory protein-2 (MIP2),
C-X-C motif chemokine 1 (KC), and TNF-α from airway epithelia, increased neutrophil
infiltration, and exaggerated lung inflammation and injury. Their results gave a greater in-
sight that the reduction in pulmonary ACE2 activity increase the pathogenesis of the lungs
inflammation, as the authors indicated that this in part because of an impaired ability to in-
hibit DABK/BKB1R axis-mediated signaling and this results in more neutrophil infiltration
and more severe inflammation in the lung [62]. Authors successfully demonstrated that
rhACE2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced
lung injury in the piglet’s model. In their results, they found that animals treated with
rhACE2 were maintaining higher partial oxygen pressure (PaO2) compared to animals
that were in the control group. In addition, they noticed that pulmonary hypertension
was less pronounced. They also noticed that inflammatory markers, such as ANG-II and
tumor neurosis factor-alpha, that were subsequently increased, were returned to basal
values [63]. The rhACE2 they used was isolated and extracted in the laboratory. In 2017,
Khan et al. conducted a pilot clinical trial (NCT01597635) to test the safety of rhACE2 in
ARDS patients. In their trial, they used GSK2586881, which is an rhACE2, to investigate
attenuating acute lung injury. In their trial, they concluded that infusion of patients with
the rhACE2 caused changes in RAS biomarkers. In addition, they found that it is tolerated
well in patients with ARDS [64].
2.6. ACE-2 and CVDs
ACE-2’s main function is to counterbalance ACE and ANG-II as part of RAS. Cardiac
ACE-2 expression, as well as soluble ACE-2 levels, are altered during CVDs, and these
altered expressions are closely related to cardiac function. Since CVDs are common among
COVID-19 patients, it becomes important to reveal the possible effects of altered ACE-2
mechanism in SARS-CoV-2 virulence and cardiac injury for these patients. Most of the
relevant previous studies focused on the soluble and cardiac ACE-2 levels in diseased
states, aiming to understand how each of these expressions influences cardiac health.
In one of the early works, Donoghue and colleagues generated transgenic mice with in-
creased cardiac-specific ACE-2 expression [65]. The animals had a high incidence of sudden
death that correlated with ACE-2 expression levels. Serum ACE-2 enzymatic activity was
higher in transgenic animals compared to non-transgenic littermates, indicating that soluble
ACE-2 was released into circulation. Interestingly, ACE-2 transgene was downregulated
in surviving older animals and cardiac function was restored. The study is important in
showing that increased tissue ACE-2 expression correlates with increased soluble ACE-2.
However, other than that, transgenically increasing cardiac ACE-2 in otherwise healthy
animals is not clinically relevant. In a more clinically relevant study, Huentelman and
colleagues showed that lentiviral induced cardiac overexpression of ACE-2 protects the
heart from ANG-II-induced hypertrophy and fibrosis in rats [66–72]. Crackower and col-
leagues showed that targeted disruption of ACE-2 in mice results in a severe abnormal
cardiac contractility, increased ANG-II levels, and upregulated hypoxia-induced cardiac
gene expression [73]. Consistent with that finding, cardiac myocardial ACE-2 expression
significantly increases in failing cardiomyopathic hearts compared to healthy controls [74],
suggesting the need for an active compensatory mechanism in RAS to preserve heart
function for these patients. More recently, Bos and colleagues also demonstrated a 5-fold
increase in myocardial ACE-2 expression for obstructive hypertrophic cardiomyopathy
patients [4]. Similar findings were presented by Chen and colleagues at both gene and
protein levels for basic heart failure [75].
Regarding soluble ACE-2, interestingly, Epelman, and colleagues showed that in-
creased ACE-2 plasma activity strongly correlates with a heart failure diagnosis, compared
to healthy individuals [76]. In a following study, the same group measured soluble ACE-2
activity in patients with chronic systolic heart failure, and showed that elevated plasma
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ACE-2 activity is associated with more severe myocardial dysfunction [77]. Increased
soluble ACE-2 levels were observed in a variety of other CVDs as well. Soro-Paavonen
and colleagues revealed increased circulating ACE-2 activity in patients suffering from
micro- and macrovascular complications associated with type 1 diabetes [78]. Walters
and colleagues examined plasma ACE-2 enzyme levels for atrial fibrillation patients, and
showed that increased plasma ACE-2 activity is associated with atrial fibrillation and more
advanced left atrial structural remodeling [79]. Li and colleagues revealed elevated serum
ACE-2 concentration in hypertension patients compared to in healthy individuals [80].
Soluble ACE-2 levels correlated well with cardiac remodeling as found from left atrial
diameter, left ventricular end-diastolic diameter, and left ventricular mass for hypertensive
patients. These findings demonstrated increased soluble ACE-2 in a variety of CVDs,
suggesting that a cardioprotective arm of the RAAS system is active in these conditions.
Since none of these studies examined soluble and cardiac ACE-2 levels simultaneously, it is
not clear whether elevated soluble ACE-2 activity is due to increased expression of tissue
ACE-2 and then shedding into the circulation, or the elevated circulating ACE-2 is a result
of a loss of protective ACE-2 from the tissue, exacerbating the cardiac injury.
In the context of COVID-19, it is not clear how SARS-CoV-2 infection affects ACE-2 levels
for already abnormal expressions due to CVDs, and whether this plays a role in virulence and
cardiac complications. The effect of SARS-CoV-2 infection on the circulatory system other than
the lung is not established [81]. The myocardial dysfunction in COVID-19 can be indirect, as a
consequence of severe lung injury and reduced oxygen supply, or cytokine storm following the
SARS-CoV-2 infections [82]. The effect can also be direct, due to decreased ACE-2 expression
and activity in the heart following myocardial infection. Oudit and colleagues studied
whether SARS-CoV can infect myocardial tissue to cause myocarditis [83]. For wild-type mice,
following the pulmonary infection, SARS-CoV was present in the heart. Interestingly, virus
levels in the heart were reduced in ACE-2 knockout mice, suggesting myocardial infection is
ACE-2-dependent. Myocardial infection in wild-type mice also induced partial ACE-2 mRNA
downregulation and a complete loss of myocardial ACE-2 protein. In the same study, the
authors analyzed the SARS-CoV virus and ACE-2 expression in autopsied heart samples from
patients who died from the infection. SARS-CoV virus and myocardial inflammation were
present in seven out of 20 samples analyzed. Similar to animal experiments, SARS-CoV was
present in the myocardial tissue, and myocardial ACE-2 protein expression was markedly
downregulated. Similar investigations are needed for SARS-CoV-2 to reveal whether the virus
is capable of causing myocardial infection. Myocarditis is not common among COVID-19
patients, and even for a few reported cases, it is not clear whether the infection is caused by
the SARS-CoV-2 virus [84]. Endothelial dysfunction and inflammation, on the other hand,
seem to be common among COVID-19 patients, as clearly seen from the high incidence of
thrombotic complications [85]. In addition to the thrombotic events, central and peripheral
nervous manifestation are frequent in patients with COVID-19 [86]. However, even for these
cases, it is not clear whether these complications are caused by a direct viral infection or are
secondary to other complications.
It is most likely that cardiac complications due to SARS-CoV-2 are due to altered
ACE-2 mechanism. Several current studies suggest that increasing particularly soluble
ACE-2 is a logical approach for protection against SARS-CoV-2-related cardiac compli-
cations. Administrating recombinant human ACE-2 to pulmonary arterial hypertension
patients demonstrated hemodynamic improvement [87]. One interesting fact is that women
have increased serum ACE-2 compared to men, and women seem to have milder symp-
toms of COVID-19. In addition, the aging population seems to have less soluble ACE-2.
Again, children usually present milder symptoms and are asymptomatic for SARS-CoV-2
infection [61]. A correlation seems to exist between age and severity of COVID-19. This
correlation may not only be due to the declining immune system for the elderly, but also
be because of a specific plasma ACE-2 profile for children. Therefore, in addition to hemo-
dynamic benefits, circulating ACE-2 may be helping children, women, and asymptomatic
COVID-19 patients to better deal with the virus by buffering it in the circulation similar
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to neutralizing antibodies. Human recombinant soluble ACE-2 is suggested as a feasible
approach to decreasing the severity of viral infection and cardiovascular improvement.
In that context, Monteil and colleagues showed that clinical-grade human recombinant
soluble ACE-2 can efficiently prevent SARS-CoV-2 viral infection and growth for Vero E6
cells [88]. They also showed that viral growth within SARS-CoV-2-infected human blood
vessel organoids and kidney organoids can be significantly inhibited via administration of
soluble ACE-2 at the early stage of infection.
2.7. Altered ACE-2 Expression with Certain Medications: Is There Evidence of Altered Expression
and SARS-CoV-2 Virulence?
As summarized in the previous section, ACE-2 overexpression can prevent and even
reverse heart failure phenotype. ACE-2 downregulation, on the other hand, can accelerate the
progression of heart failure [82]. Relevant to COVID-19, ACE-2 expression, and susceptibility to
SARS-CoV infection seem to correlate well from in vitro studies [22]. However, up to date, no
direct in vivo evidence has been provided for such a correlation. Nevertheless, following the
discovery of the SARS-CoV-2 virus utilizing ACE-2 for cell entry, significant attention has been
directed to ACE-2, and to clinical drugs that are thought to affect ACE-2 levels.
Hypertension is among the most common comorbidities for COVID-19 patients.
ARBs and ACEi are the most commonly prescribed class of medication for hypertension.
In addition to their main pharmacological effect to block the ANG-II type 1 receptor or to
inhibit ACE, interestingly, several studies have suggested that these drugs may upregulate
the expression of ACE-2 as well [82] (Figure 6). Accepting that ACE-2 expression correlates
with the susceptibility to SARS-CoV-2 infection, one would assume that ACEis/ARBs
might increase the risk of SARS-CoV-2 infection. But is this the case? To answer this
question, first, it should be known whether ACEis/ARBs increase ACE-2 levels in clinical
settings. Then, evidence should be provided if increased ACE-2 increases virulence.
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Akhtar and colleagues have recently reviewed the studies on clinical drugs affecting
ACE-2 levels [89]. The authors confirmed that most relevant studies were on animals, and
these showed that both ACEi and ARBs increased circulating as well as cardiac ACE-2
levels. Assuming these medications increase cardiac ACE-2 in clinical settings in a similar
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manner to animal experiments, and also increased cardiac ACE-2, would mean more
viral infection in the heart, and SARS-CoV-2-related myocarditis would be a common
complication for COVID-19 patients under ACEi/ARB. However, other than a few reports,
this is not the case [84]. So far, there are only a few epidemiological studies for ACEi/ARB
medication for COVID-19 patients. Xiao and colleagues assessed epidemiology and disease
severity for hypertensive COVID-19 patients under ACE/ARB, and compared with patients
under other hypertension medication [90]. Even though the cohort size was small, with
42 patients, the authors confirmed that patients under ACEi/ARB therapy had a lower
incidence of severe diseases and also lower levels of IL-6 in peripheral blood, supporting
the benefit of using ACEis or ARBs for improving the clinical outcomes of hypertensive
COVID-19 patients.
While originally it was speculated that ACEi/ARBs-related upregulation of ACE-2
would result in more severe disease outcomes for COVID-19 patients, conversely, most
current studies show that ACEi/ARB either has a neutral or beneficial effect for COVID-19
hypertensive patients in comparison. Guo and colleagues performed a meta-analysis of
the current studies to explore whether the use of ACEi/ARB was associated with disease
severity and mortality in COVID-19 patients with hypertension [91]. An analysis of nine
studies involving 3936 patients showed that ACEi/ARB therapy did not aggravate disease
severity, and it could even decrease the mortality of COVID-19 patients. For a cohort of
205 patients, Bean and colleagues showed that ACEi treatment was associated with reduced
severe disease risk [92]. Salah and colleagues analyzed 12 studies involving 16,101 patients,
and showed that the use of ACEi and ARBs improves mortality for hypertensive COVID-19
patients, with similar outcomes between ACEis and ARBs in the studied population [93].
Gao and colleagues examined 2877 patients admitted to Huo Shen Shan Hospital, a hospital
dedicated to the treatment of COVID-19 in Wuhan, China [94]. The analysis revealed that
the use of ACEi/ARB is associated with a lower risk of mortality. Mehra and colleagues
performed a similar observational study for 169 hospitals in Asia, Europe, and North
America, and studied the relationship of CVDs and drug therapy with in-hospital death
among hospitalized patients with COVID-19 [95]. Authors found no increased risk of
in-hospital death with the use of ACEi or ARBs. Zhang and colleagues performed a multi-
center retrospective study including 1128 adult patients with hypertensive COVID-19
patients, and showed that inpatient use of ACEI/ARB was associated with a lower risk of
all-cause mortality compared to ACEi/ARB non-users [96].
To sum up, present evidence suggests that ACEi/ARBs may increase the expression
and activity of cardiac ACE-2 as well as soluble ACE-2, performing a protective role in the
cardiovascular system, as seen clearly from several meta-analyses. However, the effect of
these drugs on ACE-2 in other organs, in particular, whether they could affect the expres-
sion and activity of pulmonary ACE-2, remains unknown. Assuming ACEi/ARBs may
upregulate the expression and activity of ACE-2 in the lungs, this may have a protective in-
fluence against acute lung injury due to SARS-CoV-2 infection, as explained in the previous
section [82]. Alternatively, Exogenous supplement of recombinant human ACE-2 is a useful
approach in the treatment of COVID-19, especially for those patients with cardiovascular
diseases. Increasing ACE-2 levels with ACE-2-increasing medication is another approach
that needs further exploration (Figure 7). Furthermore, recently, Inchingolo and colleagues
revealed that improving immune system along with sartans as adjuvant therapy potentially
prevented COVID-19 infection [97].
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SARS-CoV and SARS-CoV-2. While previous investigations are mostly on SARS-CoV, infection
mechanisms can be assumed to apply to SARS-CoV-2 due to the high resemblance of S-proteins
RBD domains. Even though ACE-2 is expressed in a variety of different tissues throughout
the body, the lung is the primary target for SARS-CoV-2. There is no evidence for increased
susceptibility to viral infection due to an ACE-2 upregulation for lung as well as for other
ACE-2-expressing tissues. Conversely, viral infection decreases pulmonary ACE-2, which is the
primary cause of ARDS and lung complications in COVID-19. In addition to its role in viral
infection, ACE-2 has an important function in RAAS to control ANG-II levels. Disruption of
the ACE-2 mechanism seems to be the primary cause of adverse cardiac events in COVID-19.
Increasing both soluble and tissue-specific (lung and cardiac) ACE-2 levels will have a protective
influence against COVID-19 and related complications.
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